Abstract
Weight gain is increasingly recognized as an unwanted side effect of atypical antipsychotic drugs. To explore the mechanisms underlying this side effect, we examined the effects of olanzapine, an atypical antipsychotic drug, on cellular proliferation and differentiation in the adult mouse hypothalamus. A 6-week treatment with olanzapine resulted in a significant increase in body weight. The sizes and numbers of olanzapine-treated mouse adipocytes were significantly larger than those of control mice. No significant differences were observed in the levels of blood insulin, cholesterol, triglyceride, leptin, and ghrelin among olanzapine-, haloperidol-treated and control mice with an exception that adiponectin was significantly higher in olanzapine group than control group. Body temperature and the level of uncoupling protein 2 were also comparable between the olanzapine-treated and control groups. We found that the treatment increased BrdU-incorporating cell numbers in the hypothalamus, while the same regimen with haloperidol or control had little effect on cellular proliferation. Double-labeling immunohistochemistry revealed that the majority of the BrdU-positive cells were also Olig2- or APC-positive, indicating that oligodendro...Continue Reading
References
Apr 1, 1997·Neuroendocrinology·C TangS F Leibowitz
Dec 31, 1997·Brain Research. Brain Research Protocols·Y MasuoJ Noguchi
Sep 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·F DoetschA Alvarez-Buylla
Feb 26, 2000·Science·F H Gage
Aug 11, 2000·General Hospital Psychiatry·A I GreenG Blackburn
Oct 2, 2001·The American Journal of Psychiatry·U EderW W Fleischhacker
Nov 28, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Karin HedenmalmOlav Spigset
Jun 20, 2003·Biological Psychiatry·Patrick R HofKenneth L Davis
Jul 8, 2003·Psychopharmacology·Tonmoy SharmaVeena Kumari
Sep 19, 2003·Lancet·Dmitri TkachevSabine Bahn
Sep 27, 2003·The European Journal of Neuroscience·Pei-Juan ShenAndrew L Gundlach
Jan 30, 2004·Diabetes Care·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Apr 3, 2004·Current Drug Targets·T BaptistaL Hernández
Oct 13, 2004·Biological Psychiatry·Masafumi KodamaRonald S Duman
Dec 31, 2004·The American Journal of Psychiatry·Karen A GrahamJoyce B Harp
Mar 22, 2005·Psychopharmacology·G D CooperA J Goudie
Mar 30, 2005·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M B CopeD B Allison
Oct 29, 2005·Science·Maia V KokoevaJeffrey S Flier
May 30, 2006·Schizophrenia Research·William ByneVahram Haroutunian
Jan 11, 2007·Molecular Psychiatry·J Minet-RinguetR de Beaurepaire
Sep 4, 2008·The American Journal of Psychiatry·Bruce E WexlerBradley S Peterson
Sep 26, 2008·Journal of Neuroscience Research·Kouko TatsumiAkio Wanaka
Dec 9, 2008·Lancet·Stefan LeuchtJohn M Davis
Feb 6, 2010·Obesity·Robert J FountaineDavid A Fryburg
Citations
Aug 27, 2013·Life Sciences·Fang FangXin-Min Li
Apr 26, 2011·European Journal of Pharmacology·Johann GuillemotDidier Vieau
Jun 6, 2014·Diabetes·Melissa L BorgMatthew J Watt
Aug 16, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Sohei KimotoToshifumi Kishimoto
Aug 21, 2013·Psychoneuroendocrinology·Qingsheng ZhangXu-Feng Huang
Mar 13, 2014·Psychiatry Research·Handi ZhangXin-Min Li
Nov 21, 2012·The International Journal of Neuropsychopharmacology·Yuan RenLan Xiao
Jul 5, 2011·Expert Review of Neurotherapeutics·Mark WalterfangChristos Pantelis
Mar 11, 2020·Pharmaceuticals·Christian CarpénéMaria José Garcia-Barrado
Mar 25, 2018·European Archives of Psychiatry and Clinical Neuroscience·Natalya S Kolomeets, Natalya A Uranova